FDA Approves New Device to Screen Dense Breasts
The FDA has approved a new ultrasound device to detect breast cancer in women with dense breasts. It will be used in conjunction with standard mammography in asymptomatic women with a negative mammogram.
The FDA has approved a new ultrasound device, the somo-v Automated Breast Ultrasound System (ABUS), to detect breast cancer in women with dense breasts. It will be used in conjunction with standard mammography in asymptomatic women with a negative mammogram.
The device has a specially shaped transducer that scans the whole breast in 1 minute, and produces multiple images, according to the FDA.
In a test conducted by U-Systems, the product’s manufacturer, 200 asymptomatic women with dense breasts were examined by radiologists, with some screened with traditional mammography and some screened with both mammography and the somo-v ABUS. The use of supplemental ultrasound images increased breast cancer detection by nearly 30%.
And FDA advisory committee unanimously voted to approve the device, but stated that women with previous breast surgeries or biopsies should not generally be screened with the device, since the breast tissue may be altered, increasing the chance of a false positive result.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Unveiling the complexities of preterm birth risk from nativity, ethnicity, and race
March 22nd 2024A recent study dissected the relationships between maternal nativity, ethnicity, and race in influencing preterm birth rates, shedding light on disparities and suggesting avenues for future research.
Read More
Study reveals link between opioid dosage and spontaneous preterm birth risk
February 21st 2024Recent research highlighted an association between the total dose of prescribed opioids during pregnancy and the heightened risk of spontaneous preterm birth, emphasizing the need for judicious opioid use in pain management for expectant mothers.
Read More
